Back to Crohns Disease And Colitis

NCT03467958

NCT03467958
Terminated Phase 3 🇦🇺 Australian site

Who may be able to join

Who might be able to join this trial:

  • You did not fully respond to (or achieve remission from) a related induction study after 12 weeks of treatment
  • You experienced a return of symptoms (relapse) during or after completing a related maintenance study
  • You have already completed a study of ozanimod for Crohn's Disease and meet the specific requirements to continue into this study

Who may not be able to join:

  • You have a serious ongoing condition affecting the liver, nervous system, lungs, eyes, hormones, mental health, or another major body system that could make the study unsafe or difficult to carry out (confirm with trial site)
  • You have a suspected or confirmed collection of infection (abscess) inside the abdomen or around the anal area that has not been properly treated
  • You are currently taking certain medications, specifically drugs known as CYP2C8 inducers or monoamine oxidase inhibitors (confirm with trial site if you are unsure whether your medications fall into these categories)
  • There may be additional requirements not listed here, as other criteria from the study protocol also apply (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Terminated
Phase
Phase 3
Sponsor
Celgene
Registry
clinicaltrials_gov
Start date
24 August 2018
Est. completion
31 October 2024

Where this trial is recruiting

🇦🇷 Argentina 🇦🇺 Australia 🇦🇹 Austria Belarus 🇧🇪 Belgium Bosnia and Herzegovina 🇧🇬 Bulgaria 🇨🇦 Canada 🇨🇱 Chile 🇨🇳 China 🇨🇴 Colombia 🇭🇷 Croatia 🇨🇿 Czechia 🇩🇰 Denmark 🇫🇮 Finland 🇫🇷 France 🇬🇪 Georgia 🇩🇪 Germany 🇬🇷 Greece Hong Kong 🇭🇺 Hungary 🇮🇳 India 🇮🇪 Ireland 🇮🇱 Israel 🇮🇹 Italy 🇱🇻 Latvia 🇱🇹 Lithuania 🇲🇽 Mexico Moldova 🇳🇱 Netherlands 🇵🇱 Poland 🇵🇹 Portugal 🇷🇴 Romania 🇷🇺 Russia 🇸🇦 Saudi Arabia Senegal 🇷🇸 Serbia 🇸🇰 Slovakia 🇸🇮 Slovenia 🇿🇦 South Africa 🇰🇷 South Korea 🇪🇸 Spain 🇸🇪 Sweden 🇨🇭 Switzerland 🇹🇼 Taiwan Turkey (Türkiye) 🇺🇦 Ukraine 🇬🇧 United Kingdom 🇺🇸 United States

25 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Percentage of Participants With Clinical Remission; Number of Participants With Treatment Emergent Adverse Events (TEAEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov